BioRestorative Therapies (BRTX) Fundamentals 2026 — Revenue Analysis | SniperIQ
BioRestorative Therapies (BRTX) is a US-listed Healthcare company in Biotechnology with a market capitalization of
BioRestorative Therapies (BRTX) has a market capitalization of approximately
BioRestorative Therapies's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
BioRestorative Therapies runs a net profit margin of -3089.6%, a gross margin of 92.1%, and an operating margin of -3975.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
BioRestorative Therapies reported revenue of
BioRestorative Therapies does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
BioRestorative Therapies carries a debt-to-equity ratio of 0.01x and a current ratio of 2.35x, with a market beta of 0.64. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For BioRestorative Therapies (BRTX) the key facts are: market cap
Get BioRestorative Therapies's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.